Bruker Corporation · NASDAQ:BRKR
Bruker — 37th Annual J.P. Morgan Healthcare Conference (January 2019)
28 slides from Bruker's conference presentation, Jan 7, 2019
Slide 1: Bruker Corporation (Nasdaq: BRKR)
Bruker Corporation (Nasdaq: BRKR) Bruker drives customer success and profitable growth by enabling scientific discoveries and delivering high-performance analytical, life science, pharmaceutical and diagnostic solutions. Innovation with Integrity © Bruker Corporation
Slide 2: Safe Harbor Statement
Bruker Corporation Safe Harbor Statement Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Security Exchange Act of 1934, as
Slide 3: Bruker Overview
Bruker Overview Differentiated Leader in Attractive, Diverse Life Science and Diagnostic Tools Markets Bruker revenue breakdown, % of LTM revenue(1): BIOSPIN Group NANO Group Europe • Founded in 1960, Bruker brand stands Magnetic Resonance: Advanced X-Ray for innovation NMR, EPR, Atomic Force Micros
Slide 4: Market Leading Positions in Scientific Instruments
Market Leading Positions in Scientific Instruments BRUKER HOLDS #1 OR #2 MARKET POSITION FOR ~70% OF OUR PRODUCT PORTFOLIO NMR & EPR Preclinical Imaging: MRI, MALDI BioTyper for Mass Spec Imaging, Atomic Force Spectroscopy MPI, PET/MR, microCT Microbiology MALDI-TOF & MRMS Microscopy (AFM) X-Ray Dif
Slide 5: Key Objectives for 2019-2023
Bruker Key Objectives for 2019-2023 1. Accelerate revenue growth • Enhance organic revenue growth with Project Accelerate initiatives Proteomics & Phenomics After-Market Biopharma & Applied 2. Transform portfolio with six high-growth, high-margin Project Accelerate initiatives Next-gen Nanotech Micr
Slide 6: 2019-2023 Strategy
Bruker 2019-2023 Strategy Project Accelerate and Operational Excellence drive customer success and sustainable profitable growth Profitable Growth • Managing our core business for profitable growth • Transforming the portfolio with six high-growth, high- margin Project Accelerate initiatives • Drivi
Slide 7: Portfolio Transformation
Portfolio Transformation Portfolio Reshaping our portfolio for faster growth and higher margins* 2018 2019E 2020E 2021E 2022E 2023E Proteomics & timsTOF Pro Proteomics, 1.0 GHz NMR Phenomics Mass spec based Phenomics, 1.2 GHz NMR Advanced NMR and mass spec solutions for biologics and small molecule
Slide 8: Portfolio Transformation Update: Proteomics & Phenomics Initiative
Portfolio Transformation Update Portfolio Proteomics & Phenomics Initiative Structural Biology Proteomics Phenomics by NMR by GHz-Class NMR by Mass Spec and Mass Spec • GHz+ NMR provides dynamics • timsTOF Pro trapped ion mobility • Bruker NMR is a core technology and function of proteins with PASEF
Slide 9: timsTOF Pro with PASEF enables throughput and sensitivity improvements in proteomics
Portfolio Transformation Update Portfolio timsTOFTM Pro with PASEF enables throughput and sensitivity improvements in proteomics 4D separations with timsTOF TM Pro and PASEF method - only 3.1 ng of sample amount enable superior throughput and sensitivity - corresponds to ~12 HeLa cells Examples: • >
Slide 10: Integrated NMR and MS solutions for phenomics at Murdoch University
Portfolio Transformation Update Portfolio Enabling integrated NMR and MS solutions for serum and urine phenomics at Murdoch University, Western Australia Integrated NMR, FIA-MRMS and LC-QTOF platforms to enable novel phenomics research and large cohort validation studies “Our collaboration with Bruk
Slide 11: Novel NMR Magnet at 1.1 GHz reaches field in factory test
Portfolio Transformation Update Portfolio Novel NMR Magnet at 1.1 GHz reaches field in factory test First ever high-resolution 1.1 GHz NMR spectra with novel high- temperature & low-temperature superconductor hybrid magnet 3D NMR best-TROSY-HNCACB Experiment at 1.1 GHz Expt. Time: 3.5 hours with NUS
Slide 12: Biopharma & Applied Markets Initiative
Portfolio Transformation Update Portfolio Biopharma & Applied Markets Initiative Bruker Biopharma Solutions Bruker Applied Markets Solutions • Differentiated NMR, Mass Spec, SPR, FTIR, • NMR, Mass Spec and FTIR solutions for food Raman and X-ray solutions for pharma and quality, authenticity and saf
Slide 13: Microbiology & Diagnostics Initiative
Portfolio Transformation Update Portfolio Microbiology & Diagnostics Initiative Clinical Microbiology Expanding Consumables Portfolio MALDI Biotyper identifies bacteria, yeasts and • MBT Star®-Carba and MBT Star® Cepha CE-IVD fungi accurately and with shorter time-to-result assay for antibiotic resi
Slide 14: Hain adds breadth and growth drivers to Microbiology & Diagnostics portfolio
Portfolio Transformation Update Portfolio Hain adds breadth and further growth drivers to Bruker’s Microbiology & Diagnostics portfolio • Established MDx test portfolio for Tb screening and resistance testing • MDx assays for microbial and viral pathogens Liquid Array™ • New Fluorocycler™ XT system
Slide 15: Neuroscience & Cell Microscopy Initiative
Portfolio Transformation Update Portfolio Neuroscience & Cell Microscopy Initiative Mouse spermatocyte courtesy of Jackson Labs Fluorescence Microscopy • Simultaneous, all-optical stimulation and imaging platforms for Optogenetic Neuroscience research • Next-gen Multiphoton, Super-Resolution and Lig
Slide 16: Next-Gen Nanotech & Semi Tools Initiative
Portfolio Transformation Update Portfolio Next-Gen Nanotech & Semi Tools Initiative Next-Gen Nanotechnology & Semiconductor Metrology • Logic and memory require next-gen nano-metrology tools to ensure yield and quality • Bruker next-gen atomic force microscopy (AFM) and X-ray metrology tools are key
Slide 17: Fast Growing After-Market Business
Fast Growing After-Market Business Portfolio Services, Software and Consumables Initiative Bruker Services, Software and Consumables PROGRESS UPDATE: Services, software and consumables continue to be a key growth and operating margin driver Hain majority acquisition (Oct. 2018) adds to consumabl
Slide 18: Strategically Focused M&A in 2018
Strategically Focused M&A in 2018 Portfolio M&A supports Project Accelerate, improves operating margin mix and strengthens core Higher Growth IRM2 Organic Revenue Growth Rate Lower Growth Support Core Business Transform Portfolio (ACCELERATE) *Hain Diagnostics and Mestrelab Research are majority int
Slide 19: Driving Operating Leverage through continuous Operational Excellence
Driving Operating Leverage through continuous Cost Operational Excellence: selected initiatives 2018 2019E 2020E 2021E BIOSPIN Project 2020 Lean lay-out, site consolidation 2018 - 2021E Operational Excellence and reinvestment in DE&CH & Cost Optimization CALID • Product R&D Excellence Project Green
Slide 20: 2015 to LTM Q3 2018 Financials
Bruker 2015 to LTM Q3 2018 Financials Accelerating revenue growth and healthy margin expansion drive EPS Revenue Non-GAAP Operating Margin(1) Non-GAAP EPS(1) $1.87B 16.4% $1.77B 15.9% $1.37 15.0% $1.19 $1.21 $1.62B $1.61B 13.5% $0.89 FY 2015 FY2016 FY 2017 LTM Q3 2018* FY 2015 FY2016 FY 2017 LTM Q3
Slide 21: Disciplined Capital Deployment
Disciplined Capital Deployment Leading ROIC Performance Invest in growing Maintain financial Return capital to the business flexibility shareholders Organic R&D investment Strong, flexible balance Annual dividend of Capital expenditures sheet $0.16 per share Strategically focused M&A Con
Slide 22: www.bruker.com
www.bruker.com © Bruker Corporation 22
Slide 23: Reconciliation of GAAP to Non-GAAP Financial Measures
Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (unaudited) Three Trailing Months Nine Months Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December September 30, September 30, 2015 (1) 2016 (1) 2017 (1) 2017 (1) 201
Slide 24: Reconciliation of GAAP to Non-GAAP Financial Measures
Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (Unaudited) Three Trailing Months Nine Months Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December September 30, September 30, 2015 (1) 2016 (1) 2017 (1) 2017 (1) 201
Slide 25: Reconciliation of GAAP to Non-GAAP Financial Measures
Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (Unaudited) Three Trailing Months Nine Months Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December September 30, September 30, 2015 (1) 2016 (1) 2017 (1) 2017 (1) 201
Slide 26: Reconciliation of GAAP to Non-GAAP Financial Measures
Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (Unaudited) Three Trailing Months Nine Months Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December September 30, September 30, 2015 (1) 2016 (1) 2017 (1) 2017 (1) 201
Slide 27: Reconciliation of GAAP to Non-GAAP Financial Measures
Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (Unaudited) Three Trailing Months Nine Months Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December September 30, September 30, 2015 (1) 2016 (1) 2017 (1) 2017 (1) 201
Slide 28: List of Commonly Used Abbreviations in Alphabetical Order
Bruker Corporation List of Commonly Used Abbreviations in Alphabetical Order ADC: Antibody Drug Conjugate mAb: Monoclonal Antibody AFM: Atomic Force Microscopy MALDI: Matrix Assisted Laser Desorption Ionization BEST: Bruker Energy and Supercon Technologies MALDI-TOF: Matrix Assisted Laser Desorption
Bruker — 37th Annual J.P. Morgan Healthcare Conference (January 2019) on 6ix